The short version of peptide research fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-24 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
== Reactions == Superheated water, along with supercritical water, has been used to oxidise hazardous material in the wet oxidation process. Organic compounds are rapidly oxidised without the production of toxic materials sometimes produced by combustion. However, when the oxygen levels are lower, organic compounds can be quite stable in superheated water. As the concentration of hydronium (H3O+) and hydroxide (OH−) ions are 100 times larger than in water at 25 °C, superheated water can act as a stronger acid and a stronger base, and many different types of reaction can be carried out. An example of a selective reaction is oxidation of ethylbenzene to acetophenone, with no evidence of formation of phenylethanoic acid, or of pyrolysis products. Several different types of reaction in which water was behaving as reactant, catalyst and solvent were described by Katritzky et al. Triglycerides can be hydrolysed to free fatty acids and glycerol by superheated water at 275 °C, which can be the first in a two-stage process to make biodiesel.
=== Enzymatic activity === Stabilization of tetrahedral intermediates inside of the enzyme active site has been investigated using tetrahedral intermediate mimics. The specific binding forces involved in stabilizing the transition state have been describe crystallographycally. In the mammalian serine proteases, trypsin and chymotrypsin, two peptide NH groups of the polypeptide backbone form the so-called oxyanion hole by donating hydrogen bonds to the negatively charged oxygen atom of the tetrahedral intermediate. A simple diagram describing the interaction is shown below.
==== Education ==== Even with the acceleration of the transmission of COVID-19 in the city and the increase in the occupation of beds at hospitals, Melo maintained the plan to recommence classes in municipal schools on 22 February 2021. He had only cancelled the beginning of the school year when the city had been put under the black flag category, the highest category for social distancing, due to a high risk of infections. A part of the municipal schools would return to opening at the beginning of May, even if some of the teachers had not been vaccinated, in contrast to what had been happening in neighboring cities such as Esteio and São Leopoldo. Days before, the teachers had called for protests against returning to in-person classes during the middle of the pandemic without vaccination.
== Komagataella as a model organism == In the last few years, Komagataella was investigated and identified as a good model organism with several advantages. First of all, Komagataella can be grown and used easily in lab. Like other widely used yeast models, it has relatively short life span and fast regeneration time. Moreover, some inexpensive culture media have been designed, so that Komagataella can grow quickly on them, with high cell density. Whole genome sequencing for Komagataella has been performed. The K. phaffii GS115 genome has been sequenced by the Flanders Institute for Biotechnology and Ghent University, and published in Nature Biotechnology. The genome sequence and gene annotation can be browsed through the ORCAE system. The complete genomic data allows scientists to identify homologous proteins and evolutionary relationships between other yeast species and Komagataella. In addition, all seven species were sequenced by 2022. Furthermore, Komagataella are single eukaryotic cells, which means researchers could investigate the proteins inside Komagataella. Then the homologous comparison to other more complicated eukaryotic species can be processed, to obtain their functions and origins. Another advantage of Komagataella is its similarity to the well-studied yeast model — Saccharomyces cerevisiae. As a model organism for biology, S. cerevisiae have been well studied for decades and used by researchers for various purposes throughout history.
Sources: en.wikipedia.org
== History == With the capture of Óscar Orlando Nava Valencia in October 2009 and the death of Ignacio Coronel Villarreal, of the Sinaloa Cartel in 29 July 2010, a power vacuum emerged and the Milenio Cartel (then loyal to the Sinaloa Cartel) broke into smaller factions. The most notable were the Jalisco New Generation Cartel (CJNG) headed by Nemesio Oseguera Cervantes "El Mencho" (who suspected the Sinaloa cartel had betrayed its leaders) and La Resistencia headed by Ramiro Pozos "El Molca" who switched alliances to form a brief alliance with Los Zetas (La Resistencia was founded by Sinaloa to counter Los Zetas), and started a turf war for control of the region. Some members of the Milenio Cartel, then a Sinaloa Cartel branch, who splintered and formed the CJNG were Nemesio Oseguera Cervantes (El Mencho), Érick Valencia Salazar (El 85) and Martín Arzola Ortega (El 53). With this split, a turf war against La Resistencia, headed by Ramiro Pozos (El Molca), and Los Zetas for the control of the region started. Emilio Alejandro Pulido Saldaña, better known as "El Tiburón", was considered to be a co-founder as well.
== Research == Eberlin developed a pen-like device, called the "MasSpec Pen" or "The Cancer Pen", that has demonstrated the capability to detect cancerous tissue by delivering a discrete water droplet to extract biomolecules from the tissue's surface and transporting them to a mass spectrometer for molecular analysis. The pen allows surgeons to achieve a better understanding of which tissues should be removed. As a co-principal investigator at the University of Texas at Austin, Eberlin has developed a method to detect thyroid cancer using Desorption electrospray ionization mass spectrometry (DESI-MS) imaging of fine-needle aspiration biopsies. It is two-thirds more accurate than the test already in use, fine-needle aspiration, which yields more indeterminate results when used in isolation. In addition to her work on cancer diagnosis, Eberlin has also worked with Cooks and her father on the use of mass spectrometry to quickly detect counterfeit money. Eberlin is concerned about the representation of women and diversity in science. In interviews, she has stressed the importance of women in higher levels of academia as well as leadership.
to represent these factors but it indeed is referenced to the initial stage when no action is taken to prevent the spread and all population is susceptible, thus all changes are absorbed by the change of
Sources: en.wikipedia.org
The pharmacology of ethanol involves both pharmacodynamics (how it affects the body) and pharmacokinetics (how the body processes it). In the body, ethanol primarily affects the central nervous system, acting as a depressant and causing sedation, relaxation, and decreased anxiety. The complete list of mechanisms remains an area of research, but ethanol has been shown to affect ligand-gated ion channels, particularly the GABAA receptor. After oral ingestion, ethanol is absorbed via the stomach and intestines into the bloodstream. Ethanol is highly water-soluble and diffuses passively throughout the entire body, including the brain. Soon after ingestion, it begins to be metabolized, 90% or more by the liver. One standard drink is sufficient to almost completely saturate the liver's capacity to metabolize alcohol. The main metabolite is acetaldehyde, a toxic carcinogen. Acetaldehyde is then further metabolized into ionic acetate by the enzyme aldehyde dehydrogenase (ALDH). Acetate is not carcinogenic and has low toxicity, but has been implicated in causing hangovers. Acetate is further broken down into carbon dioxide and water and eventually eliminated from the body through urine and breath. 5 to 10% of ethanol is excreted unchanged in the breath, urine, and sweat.
== Further reading == Timeline of Materials Science Archived 2011-07-27 at the Wayback Machine at The Minerals, Metals & Materials Society (TMS) – accessed March 2007 Burns, G.; Glazer, A.M. (1990). Space Groups for Scientists and Engineers (2nd ed.). Boston: Academic Press, Inc. ISBN 978-0-12-145761-7. Cullity, B.D. (1978). Elements of X-Ray Diffraction (2nd ed.). Reading, Massachusetts: Addison-Wesley Publishing Company. ISBN 978-0-534-55396-8. Giacovazzo, C; Monaco HL; Viterbo D; Scordari F; Gilli G; Zanotti G; Catti M (1992). Fundamentals of Crystallography. Oxford: Oxford University Press. ISBN 978-0-19-855578-0. Green, D.J.; Hannink, R.; Swain, M.V. (1989). Transformation Toughening of Ceramics. Boca Raton: CRC Press. ISBN 978-0-8493-6594-2. Lovesey, S. W. (1984). Theory of Neutron Scattering from Condensed Matter; Volume 1: Neutron Scattering. Oxford: Clarendon Press. ISBN 978-0-19-852015-3. Lovesey, S. W. (1984). Theory of Neutron Scattering from Condensed Matter; Volume 2: Condensed Matter. Oxford: Clarendon Press. ISBN 978-0-19-852017-7. O'Keeffe, M.; Hyde, B.G. (1996). "Crystal Structures; I. Patterns and Symmetry". Zeitschrift für Kristallographie – Crystalline Materials. 212 (12). Washington, DC: Mineralogical Society of America, Monograph Series: 899. Bibcode:1997ZK....212..899K. doi:10.1524/zkri.1997.212.12.899. ISBN 978-0-939950-40-9.{{cite journal}}: CS1 maint: periodical has ISBN (link) Squires, G.L. (1996). Introduction to the Theory of Thermal Neutron Scattering (2nd ed.). Mineola, New York: Dover Publications Inc. ISBN 978-0-486-69447-4.
In arthropods such as insects, wound healing following injury and coagulation of body fluid involves a process of melanisation of the scab, migration of cells to the scab area, and a degree of repair of the cuticle (which serves as an exoskeleton), in locusts restoring it to 2/3 of its original strength. Several vertebrates including lizards and salamanders shed their tails (autotomy) when attacked by a predator, especially if the tail is grasped, giving the animal a chance to escape. The tail is at least partially regrown over a period of weeks or months.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.